Newswires
Newswires RSS Get our newsletter
Order Prints
Newswires

Atlas of Retinal Imaging in Alzheimer’s Study

2019 MAR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Staff editors report on the newly launched clinical trial, NCT03862222, which has the following summary description: “The Atlas of Retinal Imaging in Alzheimer’s (ARIAS) study is a 5-year study examining the natural history of retinal imaging biomarkers associated with disease risk, disease burden, and disease progression in Alzheimer’s disease (AD). The objective of this project is to create a ‘gold standard’ reference database of structural anatomic and functional imaging of the retina, in order to enable the identification and development of both sensitive and reliable markers of AD risk and/or progression. Our ultimate goal is to develop a new screening protocol that identifies changes related to AD 10-20 years before AD is clinically visible.”

As a matter of record, on March 6, 2019, NewsRx staff editors report that the available information provided by University of Rhode Island on this trial include:

Tracking Information

Trial Identifier NCT03862222
First Submitted Date February 28, 2019
First Posted Date March 5, 2019
Results First Submitted Date Not Provided
Results First Posted Date Not Provided
Last Update Submitted Date February 28, 2019
Last Update Posted Date March 5, 2019
Primary Completion Date June 30, 2021
Start Date July 2019
Current Primary Outcome Measures •Structural retinal biomarkers assessed with OCT [ Time Frame: 5 years ] -- retinal nerve fiber layer (RNFL) thickness
•Structural retinal biomarkers assessed with OCT [ Time Frame: 5 years ] -- RNFL volume
•Metabolic retinal biomarkers assessed with OCT [ Time Frame: 5 years ] -- volume of retinal inclusion bodies containing beta amyloid
•Metabolic retinal biomarkers assessed with OCT [ Time Frame: 5 years ] -- surface area of retinal inclusion bodies containing beta amyloid
•Metabolic retinal biomarkers assessed with OCT [ Time Frame: 5 years ] -- macular pigment optical density (MPOD)
•vascular retinal biomarkers assessed with OCT-A [ Time Frame: 5 years ] -- vessel caliber
•vascular retinal biomarkers assessed with OCT-A [ Time Frame: 5 years ] -- vessel density
•vascular retinal biomarkers assessed with OCT-A [ Time Frame: 5 years ] -- area of foveal avascular zone
•vascular retinal biomarkers assessed with OCT-A [ Time Frame: 5 years ] -- fractal dimension
•vascular retinal biomarkers assessed with OCT-A [ Time Frame: 5 years ] -- area of blood flow
•vascular retinal biomarkers assessed with OCT-A [ Time Frame: 5 years ] -- area of blood non-flow
Current Secondary Outcome Measures •general cognition [ Time Frame: 5 years ] -- Montreal Cognitive Assessment (MoCA)
•general cognition [ Time Frame: 5 years ] -- Repeatable Battery for the Assessment of Neuropsychological Status - Update (RBANS-U)
•processing speed, attention [ Time Frame: 5 years ] -- Digit Symbol Substitution Task (DSST)
•language [ Time Frame: 5 years ] -- Redden Lab Speech/Language Task
•memory [ Time Frame: 5 years ] -- Free and Cued Selective Reminder Task (FCSRT)
•physiological [ Time Frame: 5 years ] -- blood proteomics - 21 protein panel
•physiological [ Time Frame: 5 years ] -- blood biomarkers (amyloid) measured with single molecule assay
•physiological [ Time Frame: 5 years ] -- blood biomarkers (phosphorylated tau) measured with single molecule assay
•physiological [ Time Frame: 5 years ] -- gait assessment (timed get up and go + timed get up and go dual task)
Other Outcome Measures Not Provided
Change History Complete list of historical revisions of study NCT03862222

Descriptive Information

Brief Title Atlas of Retinal Imaging in Alzheimer’s Study
Official Title Atlas of Retinal Imaging in Alzheimer’s Study
Brief Summary The Atlas of Retinal Imaging in Alzheimer’s (ARIAS) study is a 5-year study examining the natural history of retinal imaging biomarkers associated with disease risk, disease burden, and disease progression in Alzheimer’s disease (AD). The objective of this project is to create a ‘gold standard’ reference database of structural anatomic and functional imaging of the retina, in order to enable the identification and development of both sensitive and reliable markers of AD risk and/or progression. Our ultimate goal is to develop a new screening protocol that identifies changes related to AD 10-20 years before AD is clinically visible.
Detailed Description This will be a longitudinal, within-participants prospective natural history study. Participants will be recruited on the basis of serial referrals to the memory disorders centers at all three investigative sites, as well as by Institutional Review Board (IRB)-approved radio, social media and print advertisements. All participants will meet inclusion/exclusion criteria for one of the four (4) participant groups. All participants will be recruited into the study over a 24-month enrollment period. Once enrollment closes, participants will be followed for 3 years, with examinations at one of the four study locations at baseline, 12 months post-enrollment, 24 months post-enrollment, and 36 months post-enrollment. All exam and testing procedures are described below. All retinal imaging will be completed on an FDA-approved clinical OCT imaging system by trained study personnel (with quality assurance and participant safety managed by two Co-Principal Investigator (PI)’s and their staff). Pupillometry and contrast sensitivity vision testing will rely on FDA-approved and commercially widely available devices and standard clinical procedures. All techniques are well-known to both PI’s, and these techniques have been in regular use by their clinical research and/or clinical care groups for the past 6+ years. During the screening visit a cheek swab will be obtained to determine apolipoprotein (APOE) genotype. Enrollment and group assignment will be established once the genotyping results are received (i.e., approximately 55 minutes following cheek swab, and by the end of each screening visit), at which point individuals who meet enrollment criteria will be scheduled for their baseline visit. PIs may choose to include disclosure of APOE genotyping results in their location-specific protocol, if they have the appropriate clinical resources and local IRB approval for disclosure procedures. Genotyping results will not be released to participants or their physicians except through the process of an IRB approved, site-specific protocol for disclosure. At each study visit (i.e., baseline, 12 months, 24 months, and 36 months) participants will undergo an eye examination and screening for ophthalmic disease, a medical screening exam, vital signs, neuropsychological assessment, a blood sample for measurement of plasma biomarkers, and a full retinal imaging exam. All participants will be asked to provide consent to allow review of medical records, including relevant imaging (including both clinical reports and Digital Imaging and Communications in Medicine (DICOM) image files for computerized tomography (CT)/ magnetic resonance imaging (MRI) and amyloid positron emission tomography (PET) neuroimaging) and cerebrospinal fluid (CSF) biomarker evidence of AD, if available. Additional clinical and experimental endpoints will include measures of gait, sleep quality, social and psychological health, and pupillometry. Assessment of sleep architecture (i.e., actigraphy measures) will be collected via wearable trackers over the course of a 2-week period following the baseline and 36-month study visits. A subset of participants, in each of the subject groups, will be asked to take an over-the-counter herbal supplement (Longvida curcumin; Verdure Sciences, Inc., www.longvida.com) for two days prior to their baseline exams.
Study Type Observational
Study Phase Not Provided
Study Design Observational Model: Cohort
Time Perspective: Prospective
Biospecimen Retention: Samples With DNA
Description: blood draw for proteomic, biomarker, and future genome wide association study (GWAS)
Condition Alzheimer Disease
Mild Cognitive Impairment
Mild Dementia
Aging
Cognitive Change
Intervention •Other: Retinal Imaging
Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
•Other: Pupillometry
Participants will complete a task studying pupillary response to light
•Other: Contrast Sensitivity
Participants will complete a task evaluating contrast sensitivity
•Diagnostic Test: Neuropsychological Evaluation
Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
•Genetic: APOE genotyping
APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.
•Other: blood draw
Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis
•Other: Gait Assessment
Gait assessment will be conducted by trained researcher
Other Names:
⚬Timed Up and Go, Timed Up and Go - Dual Task (TUG, TUG-DT)
•Other: Actigraphy
Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
Study Arms •Cognitively normal - high risk
Adults aged 55-80 with subjective memory complaints, first degree family history of Alzheimer’s disease, and at least one copy of the APOE E4 gene, a risk gene for Alzheimer’s disease
Interventions:
⚬Other: Retinal Imaging
⚬Other: Pupillometry
⚬Other: Contrast Sensitivity
⚬Diagnostic Test: Neuropsychological Evaluation
⚬Genetic: APOE genotyping
⚬Other: blood draw
⚬Other: Gait Assessment
⚬Other: Actigraphy
•Cognitively normal - low risk
Adults aged 55-80 without subjective memory complaints, family history of Alzheimer’s disease, or genetic risk for Alzheimer’s disease.
Interventions:
⚬Other: Retinal Imaging
⚬Other: Pupillometry
⚬Other: Contrast Sensitivity
⚬Diagnostic Test: Neuropsychological Evaluation
⚬Genetic: APOE genotyping
⚬Other: blood draw
⚬Other: Gait Assessment
⚬Other: Actigraphy
•mild cognitive impairment
Adults aged 55-80 who have a confirmed diagnosis of mild cognitive impairment.
Interventions:
⚬Other: Retinal Imaging
⚬Other: Pupillometry
⚬Other: Contrast Sensitivity
⚬Diagnostic Test: Neuropsychological Evaluation
⚬Genetic: APOE genotyping
⚬Other: blood draw
⚬Other: Gait Assessment
⚬Other: Actigraphy
•mild dementia
Adults aged 55-80 with mild dementia due to probable Alzheimer’s disease.
Interventions:
⚬Other: Retinal Imaging
⚬Other: Pupillometry
⚬Other: Contrast Sensitivity
⚬Diagnostic Test: Neuropsychological Evaluation
⚬Genetic: APOE genotyping
⚬Other: blood draw
⚬Other: Gait Assessment
⚬Other: Actigraphy

Recruitment Information

Recruitment Status Not yet recruiting
Estimated Enrollment 330
Estimated Completion Date June 2024
Primary Completion Date June 30, 2021 (Final data collection date for primary outcome measure)
Eligibility Inclusion Criteria (ALL PARTICIPANTS):
•⚬ Individuals between the ages of 55 and 80 years old (inclusive).
•Permitted medications stable for at least 1 month prior to screening. In particular:
•Participants may take stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past year).
•Adequate visual and auditory acuity to allow neuropsychological testing, as determined by the eye exam and the neuropsychologist’s judgment. Hearing augmentation by hearing aids is allowed.
•Good general health or without any clinically significant abnormalities (see exclusion criteria) that would be expected to interfere with participation in the study.
•Participants must be willing and able to provide written informed consent.
•Participants must have a study partner (i.e., family member, close friend, or caregiver) who can attend study appointments with them and report on their level of daily functioning.
•As this is entirely an observational study, without treatment intervention, we will allow concurrent enrollment in other clinical trials for mild cognitive impairment (MCI) or AD, including those that involved the use of investigational drugs. Relevant information about other studies in which participants are participating (e.g., study name, sponsor) will be collected and considered as a potential statistical covariate in the statistical analysis plan (SAP). Additional Inclusion Criteria
•Healthy Control Participants
•Montreal Cognitive Assessment (MoCA) total score > 26 at screening
•Clinical Dementia Rating (CDR) 0 at screening
•An absence of substantial subjective memory complaints or worry
•No first degree relative with either diagnosed AD or suspicion of AD
•A screening genotype result showing non-carrier status for APOE e4 allele Additional Inclusion Criteria
•High-Risk for Preclinical AD Participants
•MoCA total score > 26 at screening
•CDR 0 at screening
•No clinical diagnosis of MCI or dementia of any type
•Must have all of the following three risk factors for AD:
•Subjective memory complaints as ascertained on a standardized questionnaire (i.e., ECOG).
•A positive (suspected) first-degree family history for the disease.
•A screening genotype result showing carrier status for at least one APOE e4 gene allele Additional Inclusion Criteria
•Patients with Mild Cognitive Impairment
•MoCA total score > 19 at screening
•CDR 0.5 at screening
•A clinical diagnosis of MCI (amnestic type, but may include multiple domains) from qualified specialist or from a memory disorders clinic or center
•Score of less than or equal to 85 (1.5 SD below age and education adjusted normative data) on the RBANS Delayed Memory Index (DMI)
•Positive prior biomarker evidence of Alzheimer’s disease (PET imaging or CSF study), if available Additional Inclusion Criteria
•Patients with Mild Alzheimer’s Disease
•MoCA total score > 15 and < 26 at screening
•CDR 1 at screening
•A clinical diagnosis of mild AD from qualified specialist or from a memory disorders clinic or center
•Score of less than or equal to 85 (1.5 SD below age and education adjusted normative data) on the RBANS Delayed Memory Index (DMI)
•Positive prior biomarker evidence of Alzheimer’s disease (PET imaging or CSF study), if available
•Informed consent provided from partner, caregiver or immediate family member, with verbal assent provided by individual patient. Exclusion Criteria:
•⚬ Patients with histories of other ocular or neurologic disease that could affect the results, such as unusually high refractive errors ( > or < 5.0 diopters native spherical equivalent), age related macular degeneration, diabetic retinopathy, hypertensive retinopathy, retinal vascular disease, glaucoma, optic nerve disease, cystic macular edema, large cataracts or corneal disease that may preclude visualization of the retinal fundus, substantial ocular media opacity, and/or intraocular surgery within 90 days of any study visit will be excluded.
•History of severe brain injury or other known neurologic disease or insult, which, as described by medical records, and/or as determined by the PI’s clinical judgment, has resulted in lasting cognitive sequelae that would confound the assessment and staging of potential neurodegenerative disease.
•Geriatric Depression Scale Short Form (GDS-S 15 Items) score > 6.
•Poorly controlled major depression or another psychiatric disorder within the past year.
•History of alcohol or substance abuse and/or dependence within the past 2 years (DSM-V criteria).
•History of schizophrenia or a history of psychotic features, agitation or behavioral problems within the last 3 months, which could lead to difficulty complying with the protocol.
•Participants who, in the investigator’s opinion, will not comply with study procedures.
•Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol including:
•History of systemic cancer within the past 5 years (non-metastatic skin cancers are acceptable).
•History of clinically significant liver disease, coagulopathy, or vitamin K deficiency within the past 2 years.
•History of myocardial infarction within the past six (6) months or unstable or severe cardiovascular disease including angina or congestive heart failure (CHF) with symptoms at rest.
•History of stroke(s) with lasting impairment to vision or the visual system, coagulopathy, uncontrolled hypertension (i.e., systolic BP > 170 or diastolic BP > 100) and uncontrolled or insulin requiring diabetes. Blood pressure will be recorded on the day of each examination.
•Evidence of enlarged ventricles and/or normal pressure hydrocephalus on review of medical records or inspection of CT/MRI of the brain based on previous clinical diagnosis (MRI) as noted in their neurological history
•History of Parkinson’s disease, Parkinsonism due to multiple system atrophy (MSA), progressive supranuclear palsy (PSP), Shy Drager Syndrome (SDS) or other neuro-degenerative dementias
•History of symptoms of narrow-angle glaucoma (warning signs include eye pain, restricted vision, blurred vision)
•History of elevated intraocular pressure, or medical record evidence of intraocular pressure > 20 mm Hg
•Regular (daily) use of narcotics or antipsychotic medications.
•New use of anti-Parkinsonian medications (e.g., sinemet, amantaine, bromocriptine, pergolide and selegiline) within 2 months prior to screening.
•New use of anti-convulsants (e.g., phenytoin, phenobarbital, carbamazepine) within 2 months prior to screening.
•New use of centrally active beta-blockers, narcotics, methyldopa and clonidine within 4 weeks prior to screening.
•New use of neuroleptics or narcotic analgesics within 4 weeks prior to screening.
•New and chronic use of long-acting benzodiazepines or barbiturates within 4 weeks prior to screening.
•Use of short-acting anxiolytics or sedative-hypnotics more frequently than 2 times per week within 4 weeks prior to screening (note: sedative agents should not be used within 72 hours of the baseline and follow-up visits).
•Initiation or change in dose of an antidepressant lacking significant cholinergic side effects within the 4 weeks prior to screening (use of stable doses of antidepressants for at least 4 weeks prior to screening is acceptable)
•An anticholinergic burden score of >3 on the Anticholinergic Cognitive Burden Scale (see appendix item 9.19).
•Known hypersensitivity to anticholinergic medications, including tropicamide eye drops.
Sex/Gender Sexes Eligible for Study: All
Ages 55 years to 80 years
Accepts Healthy Volunteers Yes
Contacts Primary contact: Jessica Alber, PhD, 4018742687, [email protected]
Backup contact: Alexandra Henline, , [email protected]
Listed Location Countries United States
Removed Location Countries

Administrative Information

NCT Number NCT03862222
Other Study ID Numbers 900-403-2
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
Plan to Share Data (IPD) Description Plan to make retinal atlas publicly available along with study data and retinal images.
Responsible Party Jessica Alber, University of Rhode Island
Collaborators ⚬Stuart Sinoff, MD
⚬Peter J Snyder, MD
⚬BayCare Health System
Investigators Principal Investigator: Stuart Sinoff, MD, BayCare Health System
Principal Investigator: Peter J Snyder, PhD, University of Rhode Island
Information Provided By University of Rhode Island
Verification Date February 2019

(Our reports deliver fact-based news of research and discoveries from around the world.)

Advisor News

More Advisor News

Annuity News

More Annuity News

Health/Employee Benefits News

More Health/Employee Benefits News

Life Insurance News

More Life Insurance News